TABLE 10.

Recommendations regarding other neuroimaging modalities

Imaging biomarkers of neuro-inflammation or tau pathology in dementia patients are not recommended in clinical practice. Although there is a growing body of literature supporting the use of dopamine presynaptic imaging agents for differentiating Lewy Body from AD disease, these imaging agents are not yet recommendable for clinical practice.